Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSVpreF + qIRV
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
RSVpreF + qIRV is an mRNA-based combination vaccine candidate that combines Pfizer's RSVpreF (respiratory syncytial virus prefusion F protein) vaccine with their quadrivalent modRNA-based influenza vaccine candidate (qIRV). This combination approach aims to protect against both respiratory syncytial virus (RSV) and influenza with a single vaccination, potentially simplifying immunization practices and improving vaccine uptake for both diseases.
02
Targets
Quadrivalent influenza virus hemagglutinin and neuraminidase antigensHMPV F (Human metapneumovirus fusion protein)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSVpreF + qIRV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSVpreF + qIRV.